Treatment challenges and survival analysis of human epidermal growth factor receptor 2-positive breast cancer in real world

Abstract

In spite of improvement in DFS and OS with trastuzumab, the number of patient receiving targeted therapy is very low due to financial constraints which need to be addressed to bridge the gap in survival of Her2+ patients.